Executive Briefing on Oral Oncolytics

January 29, 2015

Growth Potential, Challenges and Trade-offs
Oncology expertise from Lash Group and Xcenda are recognized in eyeforpharma's 2015 Executive Briefing. Lash Group’s Loreen Brown, offers perspective regarding the challenges of drug adherence, pricing and reimbursement, and ultimate patient impact. Insightful findings from Xcenda’s proprietary market research, PayerPulse, are also included in the article.